CytoMed Therapeutics (GDTC) Registration Filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company developing novel cell-based immunotherapies for cancer and degenerative diseases, leveraging proprietary technologies inspired by CAR-T cell successes and addressing limitations in solid tumor treatment.

• Operates as a Singapore holding company with primary business activities through subsidiaries in Malaysia, including a cGMP facility for in-house manufacturing of cell therapy products.

• Product pipeline includes CTM-N2D (CAR-gamma delta T cells), iPSC-gdNKT (iPSC-derived gamma delta NKT cells), CTM-GDT (allogeneic gamma delta T cells), and CTM-MSC (umbilical cord-derived mesenchymal stem cells).

• Business model focuses on developing “off-the-shelf” allogeneic cell therapies using healthy donor blood cells and iPSCs, aiming for broad-spectrum cancer treatment and scalability.

• Recent asset acquisition includes a Malaysian cord blood bank, expanding capabilities in stem cell banking and regenerative medicine.

Financial performance and metrics

• Initial public offering in April 2023 raised gross proceeds of $9,649,476 from 2,412,369 ordinary shares at $4.00 per share.

• As of the date of the prospectus, 11,540,000 ordinary shares are outstanding.

• The company has incurred losses since incorporation and expects significant losses for the foreseeable future, raising substantial doubt about its ability to continue as a going concern without additional funding.

Use of proceeds and capital allocation

• Net proceeds from securities sales will be used as indicated in applicable prospectus supplements, with flexibility for immediate use to implement the business plan.

• Capital allocation priorities include advancing clinical trials, expanding the product pipeline, and supporting manufacturing and research infrastructure.